Both in Pharmaceuticals
Upstream Bio vs Niagen Bioscience
Over the past year UPB returned −86.6% and NAGE returned −66.8%; their daily moves had a correlation of 0.15.
UPB −86.6% NAGE −66.8%Growth of $1, one year, split-adjusted
| Metric | UPB | NAGE |
|---|---|---|
| Price | $3.35 | $2.40 |
| Market cap | $183.5M | $189.9M |
| Today | −1.76% | +3.00% |
| 1 month | −33.5% | −14.0% |
| 6 months | −64.0% | −51.3% |
| Year to date | −87.7% | −62.3% |
| 1 year | −87.0% | −66.2% |
| Revenue growth (YoY) | −17.5% | −4.3% |
| Gross margin | 100.0% | 64.8% |
| Net margin | −5136.1% | 3.2% |
| P/E (TTM) | — | 11.9× |
| Price / sales | 58.1× | 1.5× |
| Net cash | $261.3M | $66.7M |
| Dividend yield | — | — |
| Volatility (60d) | 82.3% | 37.3% |
| Short % of float | 13.2% | 8.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).